Welcome to our dedicated page for Entera Bio news (Ticker: ENTX), a resource for investors and traders seeking the latest updates and insights on Entera Bio stock.
Entera Bio Ltd. (ENTX) is a biotechnology firm based in Israel, specializing in the development of orally delivered macromolecule therapeutics. These include peptides and therapeutic proteins aimed at treating chronic medical conditions with an unmet need. The company’s innovative approach focuses on oral administration, which has the potential to significantly change treatment paradigms.
Entera Bio's leading product candidates include EB613 and EB612. EB613 is designed to treat osteoporosis in a once-daily, oral mini tablet form of synthetic human PTH (1-34) (teriparatide). It has shown promising results in Phase 2 clinical trials, meeting both primary and secondary endpoints. Entera Bio plans to initiate a Phase 3 study for EB613 in 2024, following FDA guidelines. EB612 is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism.
Beyond these, Entera Bio is advancing several other oral peptide therapies. These include an oral oxyntomodulin tablet for obesity and an oral GLP-2 peptide tablet for rare malabsorption conditions like short bowel syndrome, in collaboration with OPKO Health.
Entera Bio leverages a proprietary technology platform that boosts the oral bioavailability of peptides, making them effective alternatives to injectable therapies. This platform is pivotal in their ongoing projects and future pipeline products, which they aim to bring to clinical phases by 2025.
In terms of financials, Entera Bio has demonstrated robust performance, as reflected in their latest financial results for the year ending December 31, 2023. The company continues to focus on strategic partnerships and advancing their research to fulfill significant unmet medical needs.
For the latest updates and news about Entera Bio Ltd., including their latest product developments and financial results, visit Entera Bio's official website.
Entera Bio reported its Q1 2024 financial results, highlighting a strong start due to its growth strategy in 2023. The company expanded its N-Tab™ therapeutic pipeline with potential first-in-class oral peptide treatments for various disorders. Entera is focused on becoming a premier oral peptide therapeutic company. Key updates include EB613 for osteoporosis, EB612 for hypoparathyroidism, and first GLP-2, GLP-1/glucagon tablets for Short Bowel Syndrome and obesity.
EB613 is the first oral PTH(1-34) daily osteoanabolic tablet for osteoporosis. EB612 is the first oral PTH(1-34) replacement therapy tablet for hypoparathyroidism. Positive in vivo PK results were announced for the oral GLP-2 tablet for Short Bowel Syndrome. Collaborative work for GLP-1/glucagon agonist tablets for obesity is ongoing. Entera also plans to use oral PTH(1-34) tablets to treat intense sport and military stress injuries.
Financially, Entera had $9.2 million in cash and cash equivalents as of March 31, 2024, with projected cash resources expected to meet operating requirements into the third quarter of 2025. Research and development expenses decreased slightly, while general and administrative expenses remained stable. The company reported a net loss of $2.0 million for the quarter.
FAQ
What is the current stock price of Entera Bio (ENTX)?
What is the market cap of Entera Bio (ENTX)?
What is Entera Bio Ltd.?
What are Entera Bio's main product candidates?
What is unique about Entera Bio's approach?
What is EB613?
What stage is EB613 currently in?
What is EB612?
Who are Entera Bio's partners?
What is Entera Bio's financial performance?
Where can I find more information about Entera Bio?
What other projects is Entera Bio working on?
